A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants with Suspected Heparin Induced Thrombocytopenia Treated with Background Standard of Care
Primary Objective
To evaluate the effects of VLX-1005 compared to placebo on platelet count recovery, an important clinical outcome in patients with positive serotonin release assay (SRA+) confirmed HIT, on a background of standard of care (SoC) anticoagulation
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Gemlyn George
Study ID
Protocol Number: 23-1265
More information available at ClinicalTrials.gov: NCT05785819
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers